985-12-6
985-12-6
Chemical Structure
Drotaverine hydrochloride
- CAS No.: 985-12-6
- Formula:C24H32ClNO4
- Molecular Weight:433.97
IUPAC Name: (Z)-1-(3,4-diethoxybenzylidene)-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride
InChIKey: JBFLYOLJRKJYNV-MASIZSFYSA-N
SMILES: CCOC1=CC2=C(C=C1OCC)CCN/C2=C\C3=CC=C(OCC)C(OCC)=C3.[H]Cl
Biological Activity: Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine (hydrochloride) exhibits in vivo antispasmodic efficacy without anticholinergic effects.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Drotaverine hydrochloride | 99.65% | Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine (hydrochloride) exhibits in vivo antispasmodic efficacy without anticholinergic effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Drotaverine hydrochloride (Standard) | ≥98% | Drotaverine (hydrochloride) (Standard) is the analytical standard of Drotaverine (hydrochloride). This product is intended for research and analytical applications. Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine (hydrochloride) exhibits in vivo antispasmodic efficacy without anticholinergic effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Drotaverine-d10 hydrochloride | Drotaverine-d10 (hydrochloride) is the deuterium labeled Drotaverine hydrochloride. Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine hydrochloride exhibits in vivo antispasmodic efficacy without anticholinergic effects. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
